Polen Capital Management
ABCL icon

Polen Capital Management’s AbCellera Biologics ABCL Stock Holding History

Polen Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-102,508
Closed -$351K – 222
2025
Q4 		$351K Sell
102,508
-166,740
-62% -$744K ﹤0.01% 203
2025
Q3 		$1.35M Buy
+269,248
New +$1.19M ﹤0.01% 121

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Polen Capital Management's ABCL Position: Q1 2026 in Review

Polen Capital Management sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 102,508 shares — an estimated $351K sold.

Polen Capital Management first reported a position in ABCL in Q3 2025 and held it in 2 quarters. The position peaked at $1.35M in Q3 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Polen Capital Management reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
  • Polen Capital Management sold 102,508 AbCellera Biologics shares in Q1 2026, an estimated $351K.
  • Polen Capital Management first reported a position in AbCellera Biologics in Q3 2025 and held it in 2 quarters.
  • Polen Capital Management's AbCellera Biologics position peaked at $1.35M in Q3 2025.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Polen Capital Management's 13F filing for Q1 2026, filed 14 May 2026.